CD19 antibody human specific - HS-439 117

B-lymphocyte antigen
Rat monoclonal purified antibody
Cat. No.: HS-439 117
Amount: 100 µg
Price: $415.00
Cat. No. HS-439 117 100 µg specific antibody, lyophilized. Affinity purified with the immunogen. Albumin and azide were added for stabilization. For reconstitution add 100 µl H2O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C to -80°C until use.
Antibodies should be stored at +4°C when still lyophilized. Do not freeze!
WB: not recommended
IP: yes
ICC: not tested yet
IHC: not tested yet
IHC-P: 1 : 1000 gallery  
Clone SY-227A1
Subtype IgG2b (κ light chain)
Immunogen Synthetic peptide corresponding to residues near the carboxy terminus of human CD19 (UniProt Id: P15391)
Reactivity Reacts with: human (P15391).
No signal: mouse (P25918), rat.
Other species not tested yet.
Data sheet hs-439_117.pdf
Cat. No.: HS-439 117
Amount: 100 µg
Price: $415.00

Immunofluorescence image of a human FFPE tonsil section stained for CD19 (B cells, red) and CD3e (T cells, green)


CD19 (Cluster of Differentiation 19) is a B cell-restricted signal-transduction molecule that plays an important role in the regulation of development, activation, and differentiation of B-lymphocytes. CD19 is considered as a biomarker for B-cells because of its continued expression from very early B cell development stages, being evident already on pro-B cells and on all later B cell stages, until plasma cell terminal differentiation, when its expression is lost. In complex with CD21 (complement receptor-2), CD81 and CD225 (Leu-13), CD19 functions as a dominant signaling receptor on the surface of mature B cells (1). CD19 is instrumental in B cell homeostasis and lowers the threshold of B cell receptor crosslinking necessary to effect B-cell activation and sustain proliferation upon antigen encounter (2). Dysregulated CD19 expression has been implicated in several autoimmune diseases and CD19 is expressed in most acute lymphoblastic leukemias (ALL), chronic lymphocytic leukemias (CLL) and other B cell lymphomas (3). Therefore, CD19 has gained attention as a potential target in the therapy of B-cell malignancies (4).

Protocols for HS-439 117